Načítá se...
An endostatin-derived peptide orally exerts anti-fibrotic activity in a murine pulmonary fibrosis model
OBJECTIVE: Pulmonary fibrosis causes high morbidity and mortality in affected individuals. Recently, we showed that parenteral or intratracheal administration of a peptide derived from endostatin, called E4, prevents and ameliorates fibrosis using different models of dermal and pulmonary disease. No...
Uloženo v:
| Vydáno v: | Int Immunopharmacol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5482421/ https://ncbi.nlm.nih.gov/pubmed/26315492 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.intimp.2015.07.039 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|